{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T10:01:12Z","timestamp":1781690472104,"version":"3.54.5"},"reference-count":32,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["R21 CA131927"],"award-info":[{"award-number":["R21 CA131927"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["K07 CA119108"],"award-info":[{"award-number":["K07 CA119108"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"name":"P30 Cancer Center Support Grant at the Yale Comprehensive Cancer Center"},{"name":"Applied Research Program"},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Office of Research, Development and Information"},{"DOI":"10.13039\/100005227","name":"Center for Medicare and Medicaid Services","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005227","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Information Management Services, Inc."},{"name":"Surveillance, Epidemiology, and End Results Program"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.leukres.2012.07.020","type":"journal-article","created":{"date-parts":[[2012,8,20]],"date-time":"2012-08-20T13:15:35Z","timestamp":1345468535000},"page":"1370-1375","source":"Crossref","is-referenced-by-count":26,"title":["The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes"],"prefix":"10.1016","volume":"36","author":[{"given":"Rong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cary P.","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Frick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azra","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Galili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Zikria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongtao","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.leukres.2012.07.020_bib0005","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1002\/cncr.22570","article-title":"Myelodysplastic syndromes: incidence and survival in the United States","volume":"109","author":"Ma","year":"2007","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.leukres.2012.07.020_bib0010","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.leukres.2010.10.007","article-title":"Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes","volume":"35","author":"Wang","year":"2011","journal-title":"Leuk Res"},{"issue":"3","key":"10.1016\/j.leukres.2012.07.020_bib0015","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.leukres.2012.07.020_bib0020","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.leukres.2012.07.020_bib0025","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1200\/JCO.2010.30.9245","volume":"29","author":"Lubbert","year":"2011","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.leukres.2012.07.020_bib0030","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.leukres.2012.07.020_bib0035","doi-asserted-by":"crossref","first-page":"942","DOI":"10.6004\/jnccn.2008.0072","article-title":"The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines","volume":"6","author":"Greenberg","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"issue":"24","key":"10.1016\/j.leukres.2012.07.020_bib0040","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.2005.05.4346","article-title":"Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B","volume":"24","author":"Silverman","year":"2006","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.leukres.2012.07.020_bib0045","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1200\/JCO.2008.19.6550","article-title":"Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial","volume":"27","author":"Steensma","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.leukres.2012.07.020_bib0050","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1185\/03007990903076699","article-title":"Estimation of economic costs associated with transfusion dependence in adults with MDS","volume":"25","author":"Frytak","year":"2009","journal-title":"Curr Med Res Opin"},{"issue":"8 Suppl.","key":"10.1016\/j.leukres.2012.07.020_bib0055","first-page":"IV-3","article-title":"Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population","volume":"40","author":"Warren","year":"2002","journal-title":"Med Care"},{"issue":"8 Suppl.","key":"10.1016\/j.leukres.2012.07.020_bib0060","first-page":"IV-104","article-title":"Estimating health care costs related to cancer treatment from SEER-Medicare data","volume":"40","author":"Brown","year":"2002","journal-title":"Med Care"},{"issue":"9","key":"10.1016\/j.leukres.2012.07.020_bib0065","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/jnci\/djn103","article-title":"Cost of care for elderly cancer patients in the United States","volume":"100","author":"Yabroff","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"10.1016\/j.leukres.2012.07.020_bib0070","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s10552-009-9362-7","article-title":"Neighborhood socioeconomic status influences the survival of elderly patients with myelodysplastic syndromes in the United States","volume":"20","author":"Wang","year":"2009","journal-title":"Cancer Causes Control"},{"issue":"12","key":"10.1016\/j.leukres.2012.07.020_bib0075","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.leukres.2009.02.005","article-title":"Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes","volume":"33","author":"Wang","year":"2009","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.leukres.2012.07.020_bib0080","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2141.2010.08082.x","article-title":"Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C","volume":"149","author":"Fenaux","year":"2010","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.leukres.2012.07.020_bib0085","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/cncr.22508","article-title":"Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.leukres.2012.07.020_bib0090","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.critrevonc.2010.04.005","article-title":"Effects of azacitidine compared with conventional care regimens in elderly (\u226575 years) patients with higher-risk myelodysplastic syndromes","volume":"76","author":"Seymour","year":"2010","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.leukres.2012.07.020_bib0095","series-title":"International classification of diseases for oncology","year":"2000"},{"issue":"12","key":"10.1016\/j.leukres.2012.07.020_bib0100","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1097\/00005650-199912000-00008","article-title":"Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer","volume":"37","author":"Brown","year":"1999","journal-title":"Med Care"},{"issue":"1","key":"10.1016\/j.leukres.2012.07.020_bib0105","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1200\/JCO.20.1.307","article-title":"Costs of treatment for elderly women with early-stage breast cancer in fee-for-service settings","volume":"20","author":"Warren","year":"2002","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.leukres.2012.07.020_bib0110","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care"},{"key":"10.1016\/j.leukres.2012.07.020_bib0115","article-title":"Identifying specific chemotherapeutic agents in medicare data: a validation study","author":"Lund","year":"2011","journal-title":"Med Care"},{"key":"10.1016\/j.leukres.2012.07.020_bib0120","unstructured":"Surveillance Research Program. SEER*Stat software (seer.cancer.gov\/seerstat) National Cancer Institute."},{"issue":"8 Pt. 2","key":"10.1016\/j.leukres.2012.07.020_bib0125","doi-asserted-by":"crossref","first-page":"757","DOI":"10.7326\/0003-4819-127-8_Part_2-199710151-00064","article-title":"Estimating causal effects from large data sets using propensity scores","volume":"127","author":"Rubin","year":"1997","journal-title":"Ann Intern Med"},{"issue":"18","key":"10.1016\/j.leukres.2012.07.020_bib0130","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2011-04-348367","article-title":"Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma","volume":"118","author":"Griffiths","year":"2011","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.leukres.2012.07.020_bib0135","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1200\/JCO.2009.25.2395","article-title":"Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries","volume":"28","author":"Goldberg","year":"2010","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.leukres.2012.07.020_bib0140","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1182\/blood-2011-02-337964","article-title":"Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries","volume":"117","author":"Cogle","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.07.020_bib0145","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1182\/asheducation-2010.1.314","article-title":"How much? How frequent? How long? A clinical guide to new therapies in myelodysplastic syndromes","volume":"2010","author":"Blum","year":"2010","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"1","key":"10.1016\/j.leukres.2012.07.020_bib0150","doi-asserted-by":"crossref","first-page":"30","DOI":"10.6004\/jnccn.2011.0005","article-title":"Myelodysplastic syndromes","volume":"9","author":"Greenberg","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"10.1016\/j.leukres.2012.07.020_bib0155","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.leukres.2011.07.028","article-title":"Diagnostic testing, treatment, cost of care, and survival among registered and non-registered patients with myelodysplastic syndromes","volume":"35","author":"Craig","year":"2011","journal-title":"Leuk Res"},{"issue":"21","key":"10.1016\/j.leukres.2012.07.020_bib0160","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/jnci\/djn349","article-title":"Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys","volume":"100","author":"Sekeres","year":"2008","journal-title":"J Natl Cancer Inst"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261200330X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261200330X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,21]],"date-time":"2018-11-21T05:26:50Z","timestamp":1542778010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521261200330X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S014521261200330X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2012.07.020","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}